Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 61: Which form of a drug is absorbed most rapidly?

A. Aqueous solution (Correct Answer)
B. Suspension
C. Oily solution
D. Solid form

Explanation: The rate of drug absorption is primarily governed by the physical state of the dosage form. For a drug to be absorbed across biological membranes, it must first be in a molecularly dispersed state (solution). 1. Why Aqueous Solution is Correct: In an aqueous solution, the drug is already dissolved. It bypasses the time-consuming steps of disintegration (breaking down of solid forms) and dissolution (solubilizing the particles). Since the drug molecules are immediately available for passive diffusion or transport across the gastrointestinal mucosa, aqueous solutions exhibit the fastest absorption rate among the given options [1]. 2. Analysis of Incorrect Options: * Suspension (B): This consists of finely divided solid particles dispersed in a liquid. While faster than a tablet, it still requires the particles to undergo dissolution before absorption can occur. * Oily Solution (C): Drugs in oily vehicles are absorbed more slowly than aqueous ones because they must first partition out of the oil phase into the aqueous physiological fluids. In clinical practice, oily solutions are often used as "depot" injections to provide sustained release [1]. * Solid Form (D): This is the slowest. A tablet or capsule must first undergo disintegration into granules, then deaggregation into fine particles, and finally dissolution. This multi-step process significantly delays the onset of absorption [1]. NEET-PG High-Yield Pearls: * Rate-limiting step: For most poorly soluble drugs, dissolution is the rate-limiting step in absorption. * Bioavailability Hierarchy: Aqueous Solution > Suspension > Capsule > Tablet > Sustained Release [1]. * pH Partition Hypothesis: Only the unionized, lipid-soluble form of a drug crosses biological membranes efficiently. While aqueous solutions are absorbed fastest due to physical state, the drug's pKa and the local pH determine the fraction available for absorption [1].

Question 62: Steady state concentration of a drug is achieved in how many half-lives?

A. 2-3 half-lives
B. 3-4 half-lives
C. 4-5 half-lives (Correct Answer)
D. 5-6 half-lives

Explanation: ### Explanation **Concept of Steady State Concentration ($C_{ss}$)** Steady state is reached when the rate of drug administration equals the rate of drug elimination. In first-order kinetics, the time required to reach steady state depends solely on the drug's **half-life ($t_{1/2}$)** and is independent of the dose or frequency of administration [1]. **Why 4-5 half-lives is correct:** The accumulation of a drug follows a predictable mathematical curve [3]. After each half-life, the drug concentration reaches a specific percentage of the ultimate steady state: * 1 $t_{1/2}$: 50% of $C_{ss}$ * 2 $t_{1/2}$: 75% of $C_{ss}$ * 3 $t_{1/2}$: 87.5% of $C_{ss}$ * **4 $t_{1/2}$: 93.75% of $C_{ss}$** * **5 $t_{1/2}$: 96.875% of $C_{ss}$** Clinically, reaching >90% of the target concentration is considered achieving steady state. Therefore, the standard consensus in pharmacology is **4 to 5 half-lives** [2]. **Analysis of Incorrect Options:** * **A & B (2-4 half-lives):** At these stages, the drug has only reached 75–87.5% of its plateau. This is insufficient for a stable therapeutic effect for most drugs. * **D (5-6 half-lives):** While the drug is technically at steady state by this time (>98%), the "4-5" range is the standard academic and clinical benchmark used in competitive exams like NEET-PG. **High-Yield Clinical Pearls for NEET-PG:** 1. **Loading Dose:** If a rapid therapeutic effect is needed (e.g., Lidocaine in arrhythmias), a loading dose is given to bypass the 4-5 half-life delay [2]. 2. **Washout Period:** Similarly, it takes **4-5 half-lives** for a drug to be completely eliminated (97% cleared) from the body after stopping treatment. 3. **Fixed Property:** The time to reach $C_{ss}$ does **not** change if you increase the dose; only the *level* of the concentration changes, not the *time* taken to get there [1].

Question 63: Which of the following is a known inhibitor of microsomal enzymes?

A. Phenobarbitone
B. Griseofulvin
C. Sodium valproate (Correct Answer)
D. Phenytoin

Explanation: **Explanation:** The correct answer is **Sodium valproate**. This question tests the fundamental pharmacological concept of **Microsomal Enzyme Induction vs. Inhibition**, a high-yield topic for NEET-PG. **1. Why Sodium Valproate is Correct:** Sodium valproate is a potent **microsomal enzyme inhibitor**. It binds to and inhibits the Cytochrome P450 (CYP450) system in the liver. By inhibiting these enzymes, it decreases the metabolism of co-administered drugs (e.g., phenobarbitone, lamotrigine), leading to increased plasma concentrations and potential toxicity. **2. Why the Other Options are Incorrect:** * **Phenobarbitone (A):** A classic, potent enzyme **inducer**. It increases the synthesis of microsomal enzymes, leading to faster metabolism of drugs like warfarin and oral contraceptives. * **Griseofulvin (B):** An antifungal agent known to be an enzyme **inducer**. * **Phenytoin (C):** A widely used antiepileptic that acts as a powerful enzyme **inducer**. **3. High-Yield Clinical Pearls for NEET-PG:** To quickly distinguish between inducers and inhibitors, use these popular mnemonics: * **Enzyme INDUCERS (GPRS Cell Phone):** * **G**riseofulvin * **P**henytoin * **R**ifampicin * **S**moking/St. John's Wort * **C**arbamazepine * **P**henobarbitone * **Enzyme INHIBITORS (VITAMIN K):** * **V**alproate * **I**soniazid * **T**ame (Cimetidine) * **A**miodarone * **M**acrolides (except Azithromycin) * **I**t rona (Ketoconazole/Azoles) * **N**ight (Ritonavir) * **K** (Grapefruit juice) **Key Concept:** Enzyme inhibitors act rapidly (within 24 hours), whereas enzyme induction takes 1–2 weeks to manifest as it requires the synthesis of new enzyme proteins.

Question 64: An agonist has affinity for which of the following?

A. The active receptor (Correct Answer)
B. The inactive receptor
C. Both active and inactive receptors
D. Neither the active nor the inactive receptor

Explanation: ### Explanation **1. Why the Correct Answer (A) is Right:** According to the **Two-State Model** of receptor activation, receptors exist in a dynamic equilibrium between two states: the **Active state (Ra)**, which triggers a biological response, and the **Inactive state (Ri)**, which does not. An **Agonist** is a drug that has a high and selective affinity for the **Active state (Ra)**. By binding preferentially to the active receptor, it shifts the equilibrium toward the Ra state, resulting in a maximal or submaximal biological effect. **2. Why the Other Options are Wrong:** * **Option B (Inactive receptor):** An **Inverse Agonist** has a higher affinity for the **Inactive state (Ri)**. By stabilizing the inactive form, it reduces the constitutive (basal) activity of the receptor, producing an effect opposite to that of an agonist. * **Option C (Both active and inactive receptors):** A **Competitive Antagonist** has equal affinity for both the active and inactive states. Because it binds to both equally, it does not shift the equilibrium; instead, it simply prevents an agonist from binding, resulting in zero intrinsic activity. * **Option D (Neither):** If a drug has no affinity for either state, it cannot bind to the receptor and will not produce any pharmacodynamic effect. **3. High-Yield Clinical Pearls for NEET-PG:** * **Intrinsic Activity (α):** Agonists have an intrinsic activity of **1**; Antagonists have **0**; Inverse agonists have **-1**; Partial agonists have between **0 and 1**. * **Affinity vs. Efficacy:** Affinity is the ability of a drug to *bind* to a receptor, while Efficacy (intrinsic activity) is the ability to *activate* the receptor and produce a response. * **Key Example:** Phenylephrine is a full agonist at α1 receptors, while Propranolol is a competitive antagonist at β receptors.

Question 65: Absorption of which of the following antimalarial drugs increases with food intake?

A. Mefloquine (Correct Answer)
B. Artesunate
C. Chloroquine
D. Amodiaquine

Explanation: **Explanation:** The correct answer is **Mefloquine**. **Why Mefloquine is correct:** Mefloquine is a highly lipophilic antimalarial drug. The presence of **food, particularly high-fat meals**, significantly enhances its oral bioavailability and rate of absorption. This is a critical pharmacokinetic property because Mefloquine has a very long half-life (approx. 2–3 weeks); ensuring optimal initial absorption is vital for therapeutic efficacy. In clinical practice, patients are advised to take Mefloquine with a meal and a full glass of water to maximize absorption and minimize gastrointestinal irritation. **Why the other options are incorrect:** * **Artesunate (B):** This is a water-soluble artemisinin derivative. It is rapidly absorbed and metabolized to dihydroartemisinin. Its absorption is not significantly dependent on food intake. * **Chloroquine (C):** Chloroquine is almost completely and rapidly absorbed from the gastrointestinal tract regardless of food. While taking it with food may reduce GI upset, it does not significantly increase its bioavailability. * **Amodiaquine (D):** Similar to Chloroquine, it is well-absorbed orally, and its pharmacokinetics are not clinically altered by food intake to the extent seen with Mefloquine. **High-Yield NEET-PG Pearls:** * **Lumefantrine & Halofantrine:** Like Mefloquine, these drugs also show a **marked increase** in absorption when taken with fatty food. (Remember: "Fatty food favors Halofantrine/Lumefantrine/Mefloquine"). * **Atovaquone:** Another antimalarial where fatty food increases bioavailability by up to 3-fold. * **Mefloquine Side Effects:** High-yield for exams are its neuropsychiatric adverse effects (hallucinations, anxiety, and psychosis) and its contraindication in patients with epilepsy or psychiatric disorders.

Question 66: Which statement is not true regarding therapeutic drug monitoring (TDM)?

A. TDM is performed when the clinical response to a drug can be easily measured. (Correct Answer)
B. TDM is indicated for drugs with a narrow therapeutic index.
C. Digoxin is a drug for which TDM is commonly performed.
D. TDM is useful when a drug exhibits erratic pharmacokinetics.

Explanation: **Explanation:** Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in biological fluids (usually plasma) to optimize dosage. **Why Option A is the Correct Answer (The "Not True" Statement):** TDM is **not** required when the clinical response or pharmacodynamic effect of a drug can be easily and objectively measured. For example, we do not perform TDM for antihypertensives (we measure blood pressure) or oral hypoglycemics (we measure blood glucose). TDM is specifically indicated when there is **no easily measurable clinical endpoint** to gauge efficacy or toxicity. **Analysis of Other Options:** * **Option B:** Drugs with a **narrow therapeutic index** (where the dose for efficacy is close to the dose for toxicity) are the primary candidates for TDM to ensure safety. * **Option C:** **Digoxin** is a classic example of a drug requiring TDM due to its narrow therapeutic window and the fact that its toxicity (arrhythmias) can be life-threatening. * **Option D:** TDM is essential for drugs with **erratic pharmacokinetics** (large inter-individual variation in absorption, metabolism, or excretion) to tailor the dose to the specific patient’s needs. **High-Yield NEET-PG Pearls:** * **Indications for TDM:** Narrow therapeutic index, erratic pharmacokinetics, suspected non-compliance, or drugs with dose-dependent (non-linear) kinetics (e.g., Phenytoin). * **Common Drugs requiring TDM:** Lithium, Digoxin, Aminoglycosides (Gentamicin), Cyclosporine, Theophylline, and Antiepileptics (Phenytoin, Carbamazepine). * **Exceptions (No TDM needed):** Hit-and-run drugs (e.g., Reserpine, MAO inhibitors), drugs with easily measurable effects (e.g., Warfarin via PT/INR), and drugs with a wide therapeutic index (e.g., Penicillin).

Question 67: Which drug does not follow nonlinear dose-dependent saturation kinetics?

A. Paracetamol (Correct Answer)
B. Salicylates
C. Phenytoin
D. Ethanol

Explanation: **Explanation:** The question tests the concept of **Zero-order vs. First-order kinetics**. Most drugs follow first-order kinetics, where a constant fraction of the drug is eliminated per unit of time. However, some drugs exhibit **Nonlinear (Saturation) Kinetics**, also known as Michaelis-Menten kinetics. In these cases, as the dose increases, the metabolic enzymes become saturated, and the elimination shifts from first-order to zero-order (constant amount eliminated per unit time). **Why Paracetamol is the Correct Answer:** **Paracetamol (Option A)** follows **First-order kinetics** at therapeutic doses. Its elimination rate is proportional to its plasma concentration, and its half-life remains constant regardless of the dose (until toxic levels are reached, where pathways saturate leading to hepatotoxicity, but it is not classified as a classic "nonlinear" drug in standard pharmacology). **Why the Other Options are Incorrect:** The mnemonic **"WATT-PE"** (Warfarin, Alcohol, Theophylline, Tolbutamide, Phenytoin, Ethanol/Ethacrynic acid) is often used to remember drugs following zero-order/nonlinear kinetics. * **Salicylates (Option B):** At higher therapeutic doses, the glycinating and glucuronide pathways saturate, shifting it to nonlinear kinetics. * **Phenytoin (Option C):** A classic example where even a small dose increase can lead to a disproportionate rise in plasma levels due to enzyme saturation (CYP2C9). * **Ethanol (Option D):** It is metabolized by Alcohol Dehydrogenase, which saturates at very low concentrations, making its metabolism zero-order. **High-Yield Clinical Pearls for NEET-PG:** * **Zero-order kinetics:** Rate of elimination is independent of plasma concentration ($t_{1/2}$ is not constant). * **First-order kinetics:** Rate of elimination is proportional to plasma concentration ($t_{1/2}$ is constant). * **Capacity-limited elimination:** Another term for nonlinear kinetics, signifying that the body's clearance capacity is easily overwhelmed.

Question 68: Which of the following is an enzyme inhibitor?

A. Phenobarbitone
B. Cimetidine (Correct Answer)
C. Phenytoin
D. CCl4

Explanation: **Explanation:** The correct answer is **Cimetidine**. This question tests the fundamental pharmacological concept of Microsomal Enzyme Induction vs. Inhibition. **1. Why Cimetidine is correct:** Cimetidine is a classic **Cytochrome P450 (CYP450) enzyme inhibitor** [1]. It binds to the heme iron of the CYP450 system, reducing the metabolic activity of enzymes like CYP1A2, 2C9, and 2D6 [1]. This leads to decreased metabolism of co-administered drugs (e.g., Warfarin, Theophylline, Phenytoin), potentially causing toxicity [3]. **2. Analysis of Incorrect Options:** * **Phenobarbitone (Option A):** A potent **enzyme inducer**. It increases the synthesis of microsomal enzymes, leading to faster metabolism and reduced efficacy of other drugs. * **Phenytoin (Option B):** Another classic **enzyme inducer**. It is frequently tested in the context of reducing the efficacy of oral contraceptive pills (OCPs). * **CCl4 (Carbon Tetrachloride) (Option D):** This is a **hepatotoxin**, not a therapeutic enzyme inhibitor [2]. While it causes liver damage that impairs metabolism, it is categorized as a toxicological agent that causes centrilobular necrosis [2]. **3. High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**erfenadine, **A**miodarone, **M**ethylphenidate, **I**traconazole, **N**itrofurantoin, **K**etoconazole (and **C**imetidine/Ciprofloxacin) [3]. **Note:** Among H2 blockers, Cimetidine has the highest inhibitory potential; newer agents like Famotidine and Ranitidine have negligible effects on CYP450.

Question 69: What is the ability of the body to eliminate a drug called?

A. Volume of distribution
B. Clearance (Correct Answer)
C. Steady state
D. Rate of elimination

Explanation: ### Explanation **Correct Answer: B. Clearance** **Clearance ($CL$)** is defined as the volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min or L/hr). It represents the body's efficiency in eliminating a drug through various organs, primarily the kidneys and liver. Mathematically, it is expressed as: $$CL = \frac{\text{Rate of elimination}}{\text{Plasma concentration}}$$ Unlike the "rate of elimination," which describes the *amount* of drug removed (e.g., mg/min), clearance describes the *volume* of blood cleared, making it a constant parameter in first-order kinetics. **Why other options are incorrect:** * **A. Volume of Distribution ($Vd$):** This is a proportionality constant relating the total amount of drug in the body to its plasma concentration. it indicates drug distribution into tissues, not elimination. * **C. Steady State:** This is the equilibrium reached when the rate of drug administration equals the rate of drug elimination. It usually takes 4 to 5 half-lives to achieve. * **D. Rate of Elimination:** This refers to the actual mass or amount of drug (e.g., mg) excreted per unit time. In first-order kinetics, this rate changes as the plasma concentration changes, whereas clearance remains constant. **High-Yield NEET-PG Pearls:** 1. **Maintenance Dose Calculation:** Clearance is the most important parameter for determining the maintenance dose ($MD = CL \times C_{ss}$). 2. **First-order vs. Zero-order:** In **First-order kinetics** (most drugs), a constant *fraction* of drug is eliminated (Clearance is constant). In **Zero-order kinetics** (e.g., Ethanol, Phenytoin, Aspirin at high doses), a constant *amount* is eliminated (Clearance decreases as concentration increases). 3. **Total Clearance:** $CL_{total} = CL_{renal} + CL_{hepatic} + CL_{others}$.

Question 70: Fexofenadine is a metabolic product of which drug?

A. Loratadine
B. Astemizole
C. Cetirizine
D. Terfenadine (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Terfenadine** **Mechanism and Concept:** Fexofenadine is the active acid metabolite of **Terfenadine**, a second-generation H1-antihistamine. Terfenadine was originally developed as a non-sedating antihistamine; however, it was found to be a "prodrug" that undergoes extensive first-pass metabolism in the liver via the **CYP3A4** enzyme to form Fexofenadine. The clinical significance lies in safety: Terfenadine itself is cardiotoxic. It blocks delayed rectifier potassium channels ($I_{Kr}$) in the heart, leading to **QT interval prolongation** and the potentially fatal arrhythmia, **Torsades de Pointes**. This occurs especially when its metabolism is inhibited (e.g., by erythromycin or ketoconazole). Fexofenadine, however, provides the same antihistaminic benefits without the cardiotoxic effects, leading to the withdrawal of Terfenadine from most markets. **Analysis of Incorrect Options:** * **A. Loratadine:** It is a prodrug, but its active metabolite is **Desloratadine**. * **B. Astemizole:** Like Terfenadine, it was withdrawn due to QT prolongation. Its active metabolite is **Desmethylastemizole**. * **C. Cetirizine:** It is actually the active metabolite of **Hydroxyzine** (a first-generation antihistamine). **High-Yield NEET-PG Pearls:** * **Active Metabolites:** Remember the pairs: Terfenadine $\rightarrow$ Fexofenadine; Loratadine $\rightarrow$ Desloratadine; Hydroxyzine $\rightarrow$ Cetirizine. * **Cardiotoxicity:** Terfenadine and Astemizole are the classic examples of drugs causing Torsades de Pointes via CYP3A4 interactions. * **P-glycoprotein:** Fexofenadine is a substrate for P-glycoprotein, which limits its entry into the CNS, contributing to its highly non-sedating nature.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free